Everything below concerns peptide research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== History == Reslizumab was initially developed by Chuan-Chu Chou at Schering-Plough and was previously known as SCH-55700. In 1993, Chou and his group at Schering-Plough were granted the patent for the design, cloning and expression of the reslizumab drug. Ception Therapeutics acquired the drug and continued its development under the name CTx55700. In 2010, Ception Therapeutics was acquired by Cephalon for $250 million and the drug continued under development under the codename CEP-38072. In 2011, Teva Pharmaceuticals acquired Cephalon for $6.8 billion and continued the development of reslizumab.
Friedrich Engelhorn Heinrich von Brunck Carl Bosch Carl Wurster Bernhard Timm Matthias Seefelder Jürgen Strube 1990-2003 Jürgen Hambrecht 2003-2011 Kurt Bock 2011-2018 Martin Brudermüller 2018-2024 Markus Kamieth 2024–present
== Properties == Like some other aldehydes, phenylglyoxal polymerizes upon standing, as indicated by solidification of the liquid. Upon heating, this polymer "cracks" to give back the yellow aldehyde. Dissolution of phenylglyoxal in water gives crystals of the hydrate:
By distinction, West Germany then viewed itself as being within its own boundaries, not only the de facto and de jure government, but also the sole de jure legitimate representative of a dormant "Germany as whole". The two Germanies relinquished any claim to represent the other internationally, which they acknowledged as necessarily implying a mutual recognition of each other as both capable of representing their own populations de jure in participating in international bodies and agreements, such as the United Nations and the Helsinki Final Act. This assessment of the Basic Treaty was confirmed in a decision of the Federal Constitutional Court in 1973;
Bacteria have the relatively well-known secretion systems that can inject a payload (possibly a toxin) into another cell. Pseudomonas aeruginosa, for example, use a type VI secretion system to target competing microbes. The injection mechanism of bacteriophages is arguably similar to a venom. Stinging plants deliver toxins into targets. There are also more active mechanisms such as the haustorium of Cuscuta, injecting digestive enzymes to facilitate extration of nutrients. Phytopathogenic fungi use appressoria to penetrate target plants and deliver cell-killing toxins. Entomopathogenic fungi may also use appressoria to penetrate insects. Nematophagous fungi use many mechanisms to capture and penetrate the target nematode. They also produce toxins. Among protists, Coleps use specialized organelles called toxicysts to inject toxins into prey. Other protists may use extrusomes.
Sources: en.wikipedia.org
Kiwis and shorebirds with long bills probe for invertebrates; shorebirds' varied bill lengths and feeding methods result in the separation of ecological niches. Divers, diving ducks, penguins and auks pursue their prey underwater, using their wings or feet for propulsion, while aerial predators such as sulids, kingfishers and terns plunge dive after their prey. Flamingos, three species of prion, and some ducks are filter feeders. Geese and dabbling ducks are primarily grazers. Some species, including frigatebirds, gulls, and skuas, engage in kleptoparasitism, stealing food items from other birds. Kleptoparasitism is thought to be a supplement to food obtained by hunting, rather than a significant part of any species' diet; a study of great frigatebirds stealing from masked boobies estimated that the frigatebirds stole at most 40% of their food and on average stole only 5%. Other birds are scavengers; some of these, like vultures, are specialised carrion eaters, while others, like gulls, corvids, or other birds of prey, are opportunists.
== Selected publications == Bolisetty, S.; Peydayesh, M.; Mezzenga, R. (2019). “Sustainable technologies for water purification from heavy metals: review and analysis.” Chemical Society Reviews 48 (2): 463–487. Wei, G.; Su, Z.; Reynolds, N. P.; Arosio, P.; Hamley, I. W.; Gazit, E.; Mezzenga, R. (2017). “Self-assembling peptide and protein amyloids: from structure to tailored function in nanotechnology.” Chemical Society Reviews 46 (15): 4661–4708. Mezzenga, R.; Schurtenberger, P.; Burbidge, A.; Michel, M. (2005). “Understanding foods as soft materials.” Nature Materials 4 (10): 729–740. Nasrabadi, M. N.; Doost, A. S.; Mezzenga, R. (2021). “Modification approaches of plant-based proteins to improve their techno-functionality and use in food products.” Food Hydrocolloids 118: 106789. Adamcik, J.; Jung, J. M.; Flakowski, J.; De Los Rios, P.; Dietler, G.; Mezzenga, R. (2010). “Understanding amyloid aggregation by statistical analysis of atomic force microscopy images.” Nature Nanotechnology 5 (6): 423–428. Bolisetty, S.; Mezzenga, R. (2016). “Amyloid–carbon hybrid membranes for universal water purification.” Nature Nanotechnology 11 (4): 365–371. Cao, Y.; Mezzenga, R. (2019). “Food protein amyloid fibrils: origin, structure, formation, characterization, applications and health implications.” Advances in Colloid and Interface Science 269: 334–356. I. Usov, G. Nyström, J. Adamcik, S. Handschin, C. Schütz, A. Fall, L. Bergström & R. Mezzenga (2015). Understanding nanocellulose chirality and structure–properties relationship at the single fibril level.
== Biofuels == The depletion of petroleum sources and increase in greenhouse gas emissions in the twenty and twenty-first centuries has been the driving factor behind the development of biofuels from microorganisms. E. coli is currently regarded as the best option for biofuel production because of the amount of knowledge available about its genome. The process converts biomass into fuels, and has proven successful on an industrial scale, with the United States having produced 6.4 billion gallons of bioethanol in 2007. Bioethenol is currently the front-runner for alternative fuel production and uses S.cerevisiae and Zymomonas mobilis to create ethanol through fermentation. However, maximum productivity is limited due to the fact that these organisms cannot use pentose sugars, leading to consideration of E.coli and Clostridia. E.coli is capable of producing ethanol under anaerobic conditions through metabolizing glucose into two moles of formate, two moles of acetate, and one mole of ethanol. While bioethanol has proved to be a successful alternative fuel source on an industrial scale, it also has its shortcomings, namely, its low energy density, high vapor pressure, and hygroscopicity. Current alternatives to bioethanol include biobutanol, biodiesel, propanol, and synthetic hydrocarbons. The most common form of biodiesels is fatty acid methyl esters and current synthesis strategies involve transesterification of triacylglycerols from plant oils.
=== Operation Freedom's Sentinel === The 1st BCT deployed to Afghanistan in support of Operation Freedom's Sentinel from June 2017 to March 2018. Two soldiers were killed in action when their convoy was purposefully hit by a vehicle filled with explosives. The 3rd BCT deployed to Afghanistan in support of Operation Freedom's Sentinel from July 2019 to March 2020. In February 2020 soldiers from the 1st BCT, 10th Mountain Division were deployed to Afghanistan to replace the 3rd BCT as part of a unit rotation.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.